Menu Search
Equities

Sinocelltech Group Ltd

688520:SHH

Sinocelltech Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)39.48
  • Today's Change-0.39 / -0.98%
  • Shares traded4.28m
  • 1 Year change-24.41%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Sinocelltech Group Ltd grew revenues 84.46% from 1.02bn to 1.89bn while net income improved from a loss of 519.00m to a smaller loss of 396.02m.
Gross margin95.83%
Net profit margin-1.06%
Operating margin19.56%
Return on assets-0.87%
Return on equity--
Return on investment-2.70%
More ▼

Cash flow in CNYView more

In 2023, cash reserves at Sinocelltech Group Ltd fell by 677.69m. Cash Flow from Financing totalled 208.50m or 11.05% of revenues. In addition the company used 383.37m for operations while cash used for investing totalled 502.79m.
Cash flow per share--
Price/Cash flow per share--
Book value per share-0.2874
Tangible book value per share-0.7386
More ▼

Balance sheet in CNYView more

Sinocelltech Group Ltd has a Debt to Total Capital ratio of 105.20%.
Current ratio0.7091
Quick ratio0.588
Total debt/total equity--
Total debt/total capital1.05
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.